b'SARS-CoV-2 researchThe Invitrogen SARS-CoV-2 Variants Neutralizing Antibody Human 4-Plex ProcartaPlex Panel (Cat. No. EPX040-16015-901) enables detection of four neutralizing antibodies against wild type SARS-CoV-2 and the B.1.1.7 (), B.1.351 (), and P.1 () variants in a single well using Invitrogen Luminex xMAP technology. In this competitive assay, signals from biotinylated ACE2 are inversely proportional to the levels of neutralizing antibodies present (Figure 1). Simultaneous detection of multiple neutralizing SARS-CoV-2 antibodies in one assay can save time and provide a complete, holistic data set for serum samples.The variant simplex targets can be combined with the Invitrogen Human Coronavirus Ig Total11-Plex ProcartaPlex Panel to create a comprehensive 14-plex screening panel.Figure 1. Principle of the assay for detection of neutralizing antibodies specific to the spike S1 proteins of wild type SARS-CoV-2 and 3 variants.Ordering informationProduct Cat. No.Human SARS-CoV-2 Variants Neutralizing Antibody 4-Plex ProcartaPlex Panel EPX040-16015-901Human Coronavirus Ig Total 11-Plex ProcartaPlex Panel EPX110-16000-901Human SARS-CoV-2 Spike UK (B.1.1.7) Ig Total ProcartaPlex Simplex Kit EPX010-16012-901Human SARS-CoV-2 Spike SA (B.1.351) Ig Total ProcartaPlex Simplex Kit EPX010-16013-901Human SARS-CoV-2 Spike Brazil (P.1) Ig Total ProcartaPlex Simplex Kit EPX010-16014-901Find out more at thermofisher.com/sars-serologyContents Inside the Cell//Issue No. 11 5'